NCT02411435 - Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

CAB

CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.

DRUG

RIF

RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.

Trial Locations (1)

GSK Investigational Site, Overland Park